We sought to enhance the selective toxicity of tumor necrosis factor alpha (TNF α) to permit its systemic use in cancer therapy. Because ligand-targeted therapeutics have proven successful in improving the selective toxicity of drugs, we prepared a fusion protein (L19mTNF α) composed of mouse TNF α and a high-affinity antibody fragment (L19 scFv) to the extradomain B (ED-B) domain of fibronectin, a marker of angiogenesis. 
This observation paved the way for the antibody's use in both in vivo diagnostic (immunoscintigraphy) and therapeutic approaches entailing the selective delivery of radionuclides or toxic agents to tumoral vasculature. In addition, Birchler et al 20 showed that L19, chemically coupled to a photosensitizer, selectively accumulates in the newly formed blood vessels of the angiogenic rabbit cornea model and, after irradiation with near infrared light, mediates the complete and selective occlusion of ocular neovasculature.
More recently, Nilsson et al 21 reported that the immunoconjugate of L19 with the extracellular domain of tissue factor mediates selective infarction in different types of murine tumor models. Furthermore, the cytokines interleukin 2 (IL-2) and IL-12 have both shown an enhanced therapeutic efficacy if delivered as fusion proteins with L19.22,23 Finally, because L19 reacts equally well with mouse and human ED-B, it can be used for both preclinical and clinical studies. Tumor necrosis factor alpha ( TNF α) is a pleiotropic cytokine with antitumoral activity24 composed of 3 noncovalently linked TNF α monomers, each of about 17.5 kDa, that yield a compact bell-shaped homotrimer.25 TNF α exerts its effects in tumors mainly on the endothelium of the tumor-associated vasculature,26,27 with increased permeability, up-regulation of tissue factor, fibrin deposition and thrombosis, and massive destruction of the endothelial cells. [28] [29] [30] [31] [32] [33] Moreover, treatment of tumor-bearing mice with intravenous injection of TNF α induces a significant reduction of the interstitial fluid pressure of the tumor,34 a process which is instrumental to increasing the concentration of antitumoral agents at the tumor site. 28, [35] [36] [37] The systemic administration of large, therapeutically effective, doses of TNF α is not possible, however, because of the unacceptably high levels of systemic toxicity it induces. For this reason, until today, only loco-regional therapies, such as "isolated limb perfusion" (ILP), 38 have been used. Improved tumor response rates were achieved in patients with in transit melanoma metastases, using local perfusions of TNF α in combination with -interferon and melphalan. 38 Moreover, ILP with melphalan and TNF α resulted in limb salvage in patients with soft-tissue sarcoma.39 A number of approaches are presently under investigation to improve the therapeutic effects and to reduce the toxic side effects of systemically administered TNF α. These strategies include the production of engineered TNF α mutants,40 the encapsulation of TNF α in long circulating liposomes,41 and the selective delivery to and fast-protein liquid chromatography on a Superdex 200 column ( Figure 1D ). The radius (nanometers) and the molecular weight (MW; kilodaltons) of the purified fusion proteins in phosphate-buffered saline (PBS; 20 mM NaH2PO4, 150 mM NaCl, pH 7.4) were determined at 25°C, using the DynaPro Molecular Sizing Instrument (ProteinSolutions, Lakewood, NJ).
Histologic analyses
Tissue samples were both paraffin embedded for histologic analysis performed as reported by Carnemolla et al22 and snap-frozen for immunohistochemistry. For immunocytochemistry, L-M murine fibroblasts were grown in Chamberslide (Nunc, Roskilde, Denmark) and then methanol fixed. Immunohistochemistry on 4-m cryostat sections and immunocytochemistry were performed as reported by Carnemolla et al. 22 The following primary antibodies were used: monoclonal rat antimouse Ki-67 (clone TEC-3; DAKO A/S, Glostrup, Denmark), monoclonal rat antimouse CD31 (clone 13. Housing, treatment, and killing of animals followed national legislative provisions (Italian law no. 116 of 27 January 1992) for the protection of animals used for scientific purposes.
Biodistribution experiments, microautoradiography, and blood clearance rate
Radioiodination of the fusion proteins was achieved as reported by Borsi et al. 18 The radioactivity was established by using a RIASTAR -counter (Packard Instruments, Milan, Italy). After labeling, the Superdex 200 profile and the immunoreactivity test were performed.18 Nonspecific accumulation of 125Iodine in the stomach and concentration in thyroid was blocked as reported by Borsi et al. 18 Tumorbearing mice were injected in the tail vein with the radioiodinated fusion proteins in 100 L PBS. Groups of 3 animals were killed at 3, 6, 24, and 48 hours after injection. The different organs, including tumor and blood, were taken and weighed, and the radioactivity was counted to determine the percentage of injected dose per gram (%ID/g). Tissue samples were then fixed with 5% formaldehyde in PBS, pH 7.4, and processed for microautoradiographies, according to Tarli et al. 12 The blood clearance parameters of the radioiodinated antibodies were fitted with a least squares minimization procedure, using the Macintosh Program Kaleidagraph (Synergy Software, Reading PA) and the following equation: X(t) Aexp((alpha t)) Bexp((beta t)), where X(t) is the %ID/g of radiolabeled antibody at time t, as reported by Borsi et al.18 X0 was assumed to be equal to 40%, corresponding to a blood volume of 2.5 mL in each mouse.
In vivo treatments
For treatments, groups of 6 tumor-bearing mice (6-7 days after subcutaneous injection, when the tumors 53 Toxicity was evaluated on the basis of weight loss. We considered a severe toxicity to be a more than 10% weight loss within 48 hours after a single intravenous injected dose, and an acceptable toxicity to be a lower than 5% weight loss within 48 hours after a single intravenous injected dose. We found that the weight loss was 0 or lower than 5% up to 1.5 pmol/g, with no significant differences between the 2 fusion proteins and rmTNF. In the therapeutic protocols with a single compound, 1 pmol/g L19mTNF, TN11mTNF, or mTNF was used, whereas 0.7 pmol/g was used in therapies combined with other drugs.
Results

Expression, purification, and characterization of L19mTNF and TN11mTNF fusion proteins
For the preparation of L19mouse(m)TNF, we used the cDNA of the scFv L1912 and, for the control fusion protein TN11mTNF, the cDNA of the scFv TN11 ( Figure 1A -B). TN11 is directed to the C repeat of human TN-C,47 which is not expressed in the tumor models used. As shown in Figure 1B TN11mTNF, corresponding to a molecular mass of 134.4 kDa, confirming as expected that both fusion proteins were homotrimers. Both fusion proteins were tested for immunoreactivity of the scFv moiety by immunohistochemistry and ELISA, and the same immunoreactivity of the original scFvs with the respective antigens was found. Both fusion proteins were also evaluated for the biologic activity of the mTNF component by using a cytotoxic assay on L-M mouse fibroblasts. In this test we found that L19mTNF
showed a 5 to 6 times higher activity than equimolar amounts of recombinant mTNF and of the fusion protein TN11mTNF (Figure 2A ). This enhanced activity was explained by the fact that mouse L-M cells Table 1 and compared with those of the dimeric scFv L19. Although 125I-L19mTNF showed a very stable and high-level accumulation in tumors ( Figure 3A ), no accumulation of 125ITN11mTNF α was detected at any time point of the experiment ( Figure 3B ; Table 1 ).
Microautoradiographies of tumors and different organs showed specific and selective accumulation of L19mTNF α on tumor vasculature ( Figure 3D) , whereas no accumulation of TN11mTNF α was detectable in the tumor or in any other organs. Figure 3C shows the curves of the F9 tumor-to-blood ratios of the %ID/g after intravenous injection of 125I-L19mTNF α , 125I-TN11mTNF α , and 125I-L19(scFv)2.
Forty-eight hours after intravenous injection of 125I-L19mTNF α , this ratio had a value of 700, nearly 14 times higher than the value obtained using the dimeric scFv L19. Blood clearance of L19mTNF α was mediated mainly by way of the kidney, as determined by counting the urine samples, and showed a biphasic curve with an and a phase. Despite a molecular size of L19mTNF α of nearly 140 kDa, its and phase half-lives (T1/2 0.67 hour; T1/2 3.9 hours) were similar to those found for dimeric scFv L19 (T1/2 0.53 hour; T1/2 8 hours), which has a molecular mass of about 60 kDa, and much shorter than the complete L19IgG (T1/2 1.48 hours; T1/2 106.7 hours) which has a molecular mass of about 150 kDa.
Therapeutic effects of L19mTNF α
Groups of 3 F9 tumor-bearing mice were intravenously injected with 0.04, 0.25, and 1.0 pmol/g of the fusion
proteins L19mTNF α and TN11mTNF α . The control group received PBS. The animals were killed 1 hour, 5 hours, and 24 hours after treatment. Healthy organs (lung, spleen, liver, kidney, intestine, and heart) were studied histologically to reveal side effects as a result of TNF α toxicity. With the exception of small foci of hemorrhages in the lung of all treated mice 5 hours and 24 hours after treatment, no morphologic side effects were found. One hour from injection of 1.0 pmol/g, the tumor cell viability (described in "Materials and methods") was 90% in the tumors treated with TN11mTNF α and 62% in the tumors treated with L19mTNF α . These values decreased after 24 hours to about 30% in the tumors treated with TN11mTNF and to less than 6% in the tumors treated with L19mTNF α ( Figure 4A ). In the remaining vital tumor tissue, the vascular density and the cellular proliferation (Ki-67 index) were not affected.
Twenty-four hours after L19mTNF α treatment, numerous apoptotic endothelial cells were demonstrated
in the vessels of the vital tumor tissue (described in "Materials and methods"), whereas no apoptotic endothelial cells were detected in the vessels of the untreated control tumors ( Figure 4B ). Figure 4C shows the F9 tumor growth curves in mice treated with intravenous injection of 1.0 pmol/g L19mTNF α ,
TN11mTNF α , and mTNF α . The animals were treated when the tumors were about 0.4 cm3. In the PBS-treated group of control mice, the tumor volume doubling time was about 20 hours, whereas the tumor volume of the animals treated with L19mTNF α remained stable for about 4 days, and then the growth curve presented a slope similar to that of the tumors of untreated animals. This finding is consistent with the results shown in Figure 4A , showing that a single injection of 1 pmol/g L19mTNF α reduces the vital part of the tumor to about 5%.. In fact, considering that this 5% of the vital tumors still conserves a doubling time of 20 hours, it should reach the original volume in about 4 days, after which time it resumes the growth curve of the untreated controls. Tumor growth rate in the 3 groups of treated mice was evaluated by calculating the tumor doubling time53 with respect to the PBS-treated controls. The results, depicted in Figure 4D , clearly show no significant differences between TN11mTNF α and rmTNF α , whereas L19mTNF α was at least 4 times more active. In fact, a 4-fold higher dose of both rmTNF α and TN11mTNF α was necessary to achieve a response similar to that of L19mTNF α . No significant weight loss was observed in the treated animals.
Therapeutic effects of L19mTNF α in combination with L19-IL2
L19-IL2 is a recently reported fusion protein composed of the scFv L19 and interleukin 2.22 Because of the targeting ability of L19, L19-IL2 concentrates IL2 in tumors and, therefore, enhances the cytokine's therapeutic index. 22 We performed biodistribution studies in F9 tumor-bearing mice by using 0.5 g/g radioiodinated L19-IL2, administered intravenously with and without 0.7 pmol/g unlabeled L19mTNF α
or unlabeled TN11mTNF α . No specific accumulation was found in healthy organs at any time when 125I-L19-IL2 was injected alone or in combination with unlabeled L19mTNF α or TN11mTNF α (data not shown). 125I-L19-IL2 accumulation in F9 tumors was significantly more persistent and at high levels when it was co-injected with L19mTNF α (about 12%ID/g between 3 and 48 hours) than when given alone or in combination with TN11mTNF α ( Figure 5A ). This persistently high accumulation in tumors accounted for the tumor-to-blood ratio of the %ID/g of 250 at 48 hours when 125I-L19-IL2 was co-injected with unlabeled L19mTNF α , whereas, after the same time, it was less than 50 when 125I-L19-IL2 was injected alone or with unlabeled TN11mTNF α ( Figure 5C ). The effects of a combined systemic therapy using L19mTNF α and L19-IL2 are shown in Figure 5D . Groups of 6 F9 tumorbearing mice received intravenous treatments at day 7 and 10 after subcutaneous inoculation of the F9 tumor cells, when the tumor was about 0.3 cm3. The treatments entailed intravenous injections of 1 g/g L19-IL2 combined with 0.7 pmol/g L19mTNF α or TN11mTNF α . The animals' weight loss was always less than 5%. As depicted in Figure 5D , the tumors in animals treated with the combination L19-IL2 and L19mTNF α grew at a much slower rate compared with the tumors in the other groups of mice. In fact, tumors in mice receiving the 2 L19 fusion proteins showed no increase in size up to 15 days after tumor grafting.
Therapeutic effects of L19mTNF α in combination with melphalan
Melphalan is an alkylating compound widely used in combination with TNF α in the isolated limb perfusion treatment of melanomas and soft tissue sarcomas.33,38,39,54 The aim of the experiment was to establish whether a higher therapeutic synergy than that already described could be achieved by substituting TNF α with L19mTNF α . Groups of 6 F9 tumor-bearing mice were given a single intravenous injection of 0.7 pmol/g L19mTNF α , of the control fusion protein TN11mTNF α , and of rmTNF α on day 6 after tumor grafting, followed by intraperitoneal injection of 4.5 g/g melphalan 24 hours later. The tumor growth curves of animals treated with PBS, PBS and melphalan, rmTNF α and melphalan, TN11mTNF α and melphalan, and L19mTNF α and melphalan are depicted in Figure 6A . All the treatments, including melphalan alone, reduced the tumoral mass within 2 to 3 days. However, although treatment with melphalan alone or in combination with rmTNF α or TN11mTNF α induced tumor quiescence up to day 16 to 18 after tumor cell grafting and thereafter produced a growth slope similar to that seen in the PBS-treated control group, the tumors of mice treated with melphalan and L19mTNF α were quiescent up to 25 to 26 days after tumor cell grafting. Similar results were obtained by using different tumor models such as WHEI-164 fibrosarcoma ( Figure 6B ) and C51 colon adenocarcinoma (data not shown).
Discussion
TNFα is one of the most potent antitumor cytokines known. Therapeutically effective doses of TNF α cannot be given systemically, however, because of its unacceptably toxic side effects. As a result, the clinical use of TNF α has until now been limited to locoregional applications. In particular, the use of TNF α in 
